INOVIO PHARMACEUTICALS, INC. financial data

Symbol
INO on Nasdaq
Location
Plymouth Meeting, PA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 10 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 169% % -59%
Debt-to-equity 141% % 238%
Return On Assets -128% % -53%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 53,571,675 shares 105%
Common Stock, Shares, Outstanding 53,571,675 shares 106%
Common Stock, Value, Issued $53,572 USD 106%
Weighted Average Number of Shares Outstanding, Basic 52,168,694 shares 85%
Weighted Average Number of Shares Outstanding, Diluted 52,168,694 shares 85%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $182,337 USD -10%
Research and Development Expense $56,827,615 USD -29%
General and Administrative Expense $33,069,786 USD -17%
Operating Income (Loss) $89,715,064 USD 25%
Net Income (Loss) Attributable to Parent $108,092,460 USD 4.2%
Earnings Per Share, Basic -2 USD/shares 43%
Earnings Per Share, Diluted -2 USD/shares 43%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $36,567,420 USD 69%
Cash, Cash Equivalents, and Short-term Investments $50,800,000 USD -40%
Accounts Receivable, after Allowance for Credit Loss, Current $978,590 USD -47%
Assets, Current $55,180,314 USD -40%
Property, Plant and Equipment, Net $2,740,356 USD -33%
Operating Lease, Right-of-Use Asset $6,956,780 USD -18%
Other Assets, Noncurrent $2,012,476 USD 255%
Assets $69,385,656 USD -35%
Liabilities, Current $69,823,896 USD 197%
Operating Lease, Liability, Noncurrent $7,281,737 USD -27%
Liabilities $77,105,633 USD 130%
Accumulated Other Comprehensive Income (Loss), Net of Tax $647,356 USD -3.8%
Retained Earnings (Accumulated Deficit) $1,818,930,043 USD -6.3%
Stockholders' Equity Attributable to Parent $7,719,977 USD -110%
Liabilities and Equity $69,385,656 USD -35%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $26,874,027 USD 6.6%
Net Cash Provided by (Used in) Financing Activities $1,027,930 USD
Net Cash Provided by (Used in) Investing Activities $51,753 USD -100%
Common Stock, Shares Authorized 600,000,000 shares 0%
Common Stock, Shares, Issued 53,571,675 shares 106%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $25,897,850 USD -589%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $36,567,420 USD 69%
Interest Paid, Excluding Capitalized Interest, Operating Activities $0 USD -100%
Operating Lease, Liability $10,020,000 USD -19%
Depreciation $371,367 USD -13%
Payments to Acquire Property, Plant, and Equipment $59,373 USD 67%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $108,116,355 USD 4.1%
Lessee, Operating Lease, Liability, to be Paid $11,918,000 USD -22%
Operating Lease, Liability, Current $2,738,490 USD 13%
Lessee, Operating Lease, Liability, to be Paid, Year Two $2,992,000 USD -16%
Lessee, Operating Lease, Liability, to be Paid, Year One $3,592,000 USD 3.1%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $1,898,000 USD -34%
Lessee, Operating Lease, Liability, to be Paid, Year Three $2,319,000 USD -22%
Lessee, Operating Lease, Liability, to be Paid, Year Four $2,132,000 USD -7.7%
Additional Paid in Capital $1,811,803,850 USD 1.5%